1 Divisions of Rheumatology, Ophthalmology and
2 Internal Medicine, Erasmus Academic Hospital, Université Libre de Bruxelles, Brussels B-1070, Belgium
Correspondence to:
S. D. Steinfeld, Division of Rheumatology, Erasmus Academic Hospital, Université Libre de Bruxelles, 808 route de Lennick, Brussels B-1070, Belgium.
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Methods. Seven female patients (age 57±8.6 yr) with primary SS were enrolled in an open, uncontrolled trial of AZT (250 mg b.i.d.) for the treatment of primary SS. The efficacy variables were oral and ocular dryness symptoms, fatigue, tender points, physician's and patient's global assessments (GA), ocular function tests (fluorescein tear break-up time, Schirmer's test, Rose Bengal staining) and laboratory parameters [erythrocyte sedimentation rate (ESR), serum IgG, IgA and IgM].
Results. A significant improvement was observed in all subjective manifestations, as well as the objective parameters of ocular dryness. The treatment was well tolerated, except for mild and transitory gastrointestinal disturbances in 6/7 patients. Laboratory parameters did not change significantly. The clinical benefit persisted in 5/7 patients 1 month after the end of therapy.
Conclusion. AZT seems to be effective and well tolerated in patients with primary SS.
KEY WORDS: Zidovudine, Sjögren's syndrome, Retrovirus.
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Retroviruses have been implicated in the aetiology of various autoimmune diseases [2, 3]. Evidence for a pathogenic role for retroviruses in the initiation and maintenance of autoimmunity in SS includes: (a) the presence in SS patients of antibodies which are cross-reactive with retroviral gag proteins [46]; (b) the detection of retrovirus antigens in SS patients [7]; (c) the occurrence of SS-like conditions in human immunodeficiency virus (HIV) patients [8] and human T-lymphotropic virus Type I (HTLV-1)-associated disorders [9, 10]; (d) the description of intracisternal A-type retrovirus particules in salivary gland cells from SS patients [11, 12]; (e) the demonstration of a reverse transcriptase activity in salivary glands of SS patients [12]; (f) the identification of an exogenous retroviral sequence from salivary gland tissue of an SS patient [13]. Animal models also provide supportive evidence: Green et al. [14] described a sialadenitis in the HTLV-1-tax transgenic mouse and MAIDS mice develop a salivary gland lymphocytic infiltration [7, 8].
Zidovudine, the first antiretroviral agent approved for clinical use, is a thymidine analogue that inhibits retroviral replication by interfering with the viral reverse transcriptase and elongation of the viral DNA chain [15]. The administration of zidovudine (AZT) in some patients with diffuse infiltrative lymphocytosis syndrome (DILS) and HIV infection led to a diminution of salivary gland enlargement and improvement in the associated discomfort [16]. Despite the development of symptomatic therapy, no systemic treatment is still available for SS [17]. The aim of the present study was to determine the possible effects of AZT administration on primary SS disease-related signs and symptoms.
![]() |
Patients and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Approval was obtained from the local ethical board and written informed consent from the patients. Seven female patients (age 57±8.6 S.D. yr) were included in the study. Their clinical, immunological and histological characteristics are summarized in Table 1.
|
Assessment and outcome measures
Clinical, ophthalmological and biological evaluations were performed monthly for the 3 months of treatment and 1 month after the discontinuation of therapy. Clinical assessment was carried out by the same physician (SDS) and consisted of: (1) a general physical examination; (2) a dry mouth evaluation (04 scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe); (3) the need for water during speaking and the need to awaken for water drinking; (4) the speech test (number of repeated `Puttica' during 2 min; presented by P. J. Shirlaw at `New Advances in Basic Science, Diagnosis and Treatment of Sjögren's Syndrome', London, January 1997); (5) a dry eye evaluation (04 scale: 0=no symptom, 1=mild symptoms relieved by AT, 2=moderate symptoms partially relieved by AT, 3=severe symptoms partially relieved by AT, 4=severe symptoms unrelieved by AT); (6) the frequency of AT use; (7) the fatigue evaluation test by a 0100 mm visual analogue scale (VAS); (8) the tender joint count (maximum 24); (9) a muscle tender point count (maximum 18); (10) psychological status by the Hamilton scale.
Patient's and physician's global assessments were evaluated by a 0100 mm VAS.
The ophthalmological assessment was made by the same physician (PD) and consisted of fluorescein tear break-up time test (TBUT), Schirmer's test and corneal evaluation by Rose Bengal staining (09 score).
Biological parameters were measured monthly during 4 months: ESR, C-reactive protein (CRP), full blood count, renal and liver function tests, creatine kinase, serum immunoglobulins A, M and G, antinuclear antibodies (ANA) and rheumatoid factor (RF). An indirect immunofluorescence procedure using Hep2 cells was employed to detect the presence and titre of ANA (Immunoconcept, Sacramento, CA, USA). Anti-Ro/ SS-A and anti-La/SS-B antibodies were detected by ELISA (INOVA Diagnostics, San Diego, CA, USA). The serum levels of RF were evaluated by laser nephelometry (Behring, Nlatex RF, MA, USA).
Statistical analysis
The significance of differences was evaluated by paired Student's t-test (intent-to-treat analysis).
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
Dry eyes
Similarly, a subjective improvement (P<0.0001) was also observed for dry eye manifestations and the daily use of AT was rapidly reduced (P<0.01). The benefit was confirmed by all tear gland function tests, which improved significantly in six of the seven patients and were unchanged in one (P<0.02) (Table 2).
General and extraglandular symptoms
Fatigue disappeared after treatment in all patients (P<0.001), mostly during the second month of treatment. Diffuse muscular pain was reduced in all but one patient. Tender points present at entry in 6/7 patients disappeared after treatment (P<0.02). Accordingly, global assessments of the disease by the patient (P<0.001), as well as by the physician (P<0.001), improved. Dry cough, which was present in 4/7 patients at entry, disappeared in two after the second month. Raynaud's phenomenon, which was present in 4/7 patients before starting therapy, was not modified. The <10 Hamilton depression scale score at entry remained unmodified at the end of the study.
Laboratory parameters
Biological parameter values did not vary significantly.
Adverse events
No major adverse event occurred during the study. Minor side-effects were reported by 6/7 patients during the first month of treatment (between the second and third week). They comprised gastrointestinal discomfort (5/7) and mild diarrhoea (2/7) for <3 days. A reversible leucopenia was noted in one patient. None of these effects required AZT discontinuation and/or addition of symptomatic treatments.
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
AZT administration was well tolerated, except for mild and transitory gastrointestinal side-effects. AZT appears to be safe and better tolerated than the other proposed drugs for SS, such as cyclosporin A [22], methotrexate [23] or azathioprine [24]. This is, to our knowledge, the second HIV-unrelated disease which has been treated with AZT. Previously, Gill et al. [25] reported a remission in adult T-cell leukaemialymphoma related to HTLV-1 infection treated with a combination of AZT and interferon alpha.
The mechanisms by which AZT exerts a biological action in SS remain unclear. AZT is known to be active against retroviruses, but this drug could also play an immunomodulatory role [26]. In contrast to studies of hydroxychloroquine in SS [27, 28], no fall in ESR or IgG levels in the patients was observed, suggesting that the systemic course was not affected during the short period of treatment.
Many biases can be identified in such an open trial. We cannot rule out a placebo effect. However, it should be emphasized that the beneficial effects were maintained after 1 month follow-up in 5/7 patients, contrasting with very limited placebo effect found in the other trials in SS [2022]. A flare occurred in one patient after the end of the study and we decided to re-introduce AZT according to the patient's wishes. All tests improved again significantly. The encouraging results of this study support the need for multicentre randomized trials of AZT in patients with primary SS.
In conclusion, the present study suggests that AZT could be a potentially beneficial and low-risk treatment for primary SS.
![]() |
Acknowledgments |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|